Cleveland Biolabs

Cleveland BioLabs is a Clinical-stage biotechnology company focused on oncology and orphan drug development. Since its establishment in 2003, the company has been dedicated to the research, development, and commercialization of proprietary products targeting the potential treatment of cancer, prevention and treatment of acute radiation syndrome, and counteraction of the toxic effects of radio and chemotherapies for oncology patients. Presently, the company has nine product candidates in its pipeline being developed directly by them and their majority-owned subsidiaries, Incuron, LLC, and Panacela Labs, Inc. The company's focus on critical medical needs and its innovative approach to proprietary product development position it as a key player in the biotechnology and healthcare industries. Recently, Cleveland BioLabs received a significant $14.00M Post-IPO Equity investment on 19 February 2021. This investment reflects the confidence of investors in the potential of the company and its product pipeline. With its headquarters in the United States, Cleveland BioLabs continues to make strides in the development of crucial medical solutions, making it a compelling consideration for potential venture capital investments.